A Phase 2 interventional study of Brexanolone in Tinnitus, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Supernus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies in Tinnitus with a site in United States — 15 open to participants now, 19 under way, 1 of them phase 3. Tinnitus · United States.
Among the 126 studies in Tinnitus with a site in United States, this one is the 93rd largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2023, is one of 19 in phase 2, and was the 101st registered.
444 studies on the registry are indexed under Tinnitus; 98 are open to participants now.
Browse Tinnitus studies →15 of the 126 studies in Tinnitus with a site in United States are open now. Recruiting first, the newest first:
University of Illinois at Urbana-Champaign · Sites in United States
Ages 18–70
University of Central Florida · Sites in United States
Ages 18–39
Restorear Devices LLC · Sites in United States
Ages 18+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18+
Restorear Devices LLC · Sites in United States
Ages 18–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Tinnitus studies recruiting now, 21 (43%) set no upper age limit and 18 (37%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 26 · Phase 3 11 · Phase 4 4
First in 1999; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 60 across 368 interventional studies indexed under Tinnitus.
Median enrollment 40 across the 112 interventional studies, 64 across the 13 observational. Of the 95 that completed or were terminated, 58 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 126 have an industry lead sponsor. The 10 most frequent:
Supernus Pharmaceuticals, Inc. is the lead sponsor of 64 studies on the registry; 6 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
Supernus Pharmaceuticals, Inc. has 1 study filed under Tinnitus — fewer than ten, so there is no comparison to draw.
8 of the studies in Tinnitus with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06859788Phase 3Sound Pharmaceuticals, IncorporatedSPI-1005 for the Treatment of Meniere's Disease (Open Label) | 2026-12 |
| NCT07158034University of MinnesotaInvestigating EEG as a Biomarker for Tinnitus Improvement After Bimodal Stimulation | 2026-11-30 |
| NCT07071480Restorear Devices LLCNoninvasive Therapy for Tinnitus | 2026-11-30 |
| NCT04066348Wayne State UniversityTNF-α Treatment of Blast-Induced Tinnitus | 2026-12 |
| NCT07788638University of Illinois at Urbana-ChampaignNon-Invasive Neurofeedback Training to Alleviate Tinnitus Distress | 2026-12-15 |
Add all 8 to your calendar (.ics) → With an account.
Among the 126 studies in Tinnitus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability of brexanolone in participants with tinnitus following a single 6-hour continuous intravenous (IV) infusion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a 6-hour single continuous intravenous (IV) infusion of brexanolone at 30 micrograms per kilogram per hour (mcg/kg/hour) for 0 to 0.5 hours, at 60 mcg/kg/hour for 0.5 to 1 hour, and at 90 mcg/kg/hour for 1 to 6 hours, on Day 1 of the Treatment Period.
Drug: Brexanolone
Brexanolone IV infusion
Also known as: Allopregnanolone, ZULRESSO®, SAGE-547
Number of Participants With Treatment-Emergent Adverse Events (TEAE)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset after the start of brexanolone, or any worsening of a pre-existing medical condition/adverse event with onset after the start of brexanolone and throughout the study.
Time frame: Up to Day 15
Change From Baseline (Observed Value) to Hour 6 of Infusion in Visual Analog Scale-Loudness (VAS-L) Ratings
VAS-L is a subject-rated scale used to assess the perceived loudness of tinnitus. Participants answered the question "How loud is your tinnitus now?" on a horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.
Time frame: Baseline; 0.5, 1, 2, 3, 4, 5, and 6 hours during brexanolone infusion on Day 1
Change From Baseline (Model Based) to Hour 6 of Infusion in VAS-L Ratings
VAS-L is a subject-rated scale used to assess the perceived loudness of tinnitus. Participants answered the question "How loud is your tinnitus now?" on a horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. A Mixed Model Repeated Measures (MMRM) with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.
Time frame: Baseline; 0.5, 1, 2, 3, 4, 5, and 6 hours during brexanolone infusion on Day 1
Change From Baseline (Observed Value) to Hour 6 of Infusion in Visual Analog Scale-Annoyance (VAS-A) Ratings
VAS-A is a subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on a horizontal scale anchored on the left by "not annoying" (score of 0) and on the right by "extremely annoying" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.
Time frame: Baseline; 0.5, 1, 2, 3, 4, 5, and 6 hours during brexanolone infusion on Day 1
Change From Baseline (Model Based) to Hour 6 of Infusion in VAS-A Ratings
VAS-A is a subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on a horizontal scale anchored on the left by "not annoying" (score of 0) and on the right by "extremely annoying" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. A MMRM with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.
Time frame: Baseline; 0.5, 1, 2, 3, 4, 5, and 6 hours during brexanolone infusion on Day 1
Change From Baseline (Observed Value) to Post-infusion in VAS-L Ratings Measured Via Daily Diary Over Multiple Days
VAS-L is subject-rated scale used to assess perceived loudness of tinnitus. Participants answered question "How loud is your tinnitus now?" on horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100) via daily diary over multiple days. Higher scores= greater severity. Negative change from baseline= better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.
Time frame: Baseline; Days 2, 3, 4, 5, 6, and 7 after brexanolone infusion given on Day 1
Change From Baseline (Model Based) to Post-infusion in VAS-L Ratings Measured Via Daily Diary Over Multiple Days
VAS-L is subject-rated scale used to assess perceived loudness of tinnitus. Participants answered question "How loud is your tinnitus now?" on horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100) via daily diary over multiple days. Higher scores= greater severity. Negative change from baseline= better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. A MMRM with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.
Time frame: Baseline; Days 2, 3, 4, 5, 6, and 7 after brexanolone infusion given on Day 1
Change From Baseline (Observed Value) to Post-infusion in VAS-A Ratings Measured Via Daily Diary Over Multiple Days
VAS-A is subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on horizontal scale anchored on left by "not annoying" (score of 0) and on right by "extremely annoying" (score of 100) via daily diary over multiple days. Higher scores=greater severity. Negative change from baseline=better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.
Time frame: Baseline; Days 2, 3, 4, 5, 6, and 7 after brexanolone infusion given on Day 1
Change From Baseline (Model Based) to Post-infusion in VAS-A Ratings Measured Via Daily Diary Over Multiple Days
VAS-A is subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on horizontal scale anchored on left by "not annoying" (score of 0) and on right by "extremely annoying" (score of 100) via daily diary over multiple days. Higher scores=greater severity. Negative change from baseline=better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. A MMRM with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.
Time frame: Baseline; Days 2, 3, 4, 5, 6, and 7 after brexanolone infusion given on Day 1
Participants were enrolled at one active clinical site in the United States from 10 May 2023 to 21 November 2023.
| Milestone | Brexanolone |
|---|---|
| Started | 10 |
| Completed | 9 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset after the start of brexanolone, or any worsening of a pre-existing medical condition/adverse event with onset after the start of brexanolone and throughout the study.
| Participants | Brexanolone |
|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAE) | 1 |
VAS-L is a subject-rated scale used to assess the perceived loudness of tinnitus. Participants answered the question "How loud is your tinnitus now?" on a horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.
| score on a scale | Brexanolone |
|---|---|
| Change at Day 1, Hour 0.5 | -3.1 ± 8.33 |
| Change at Day 1, Hour 1 | -8.1 ± 14.13 |
| Change at Day 1, Hour 2 | -7.2 ± 14.41 |
| Change at Day 1, Hour 3 | -11.2 ± 14.54 |
| Change at Day 1, Hour 4 | -15.4 ± 16.26 |
| Change at Day 1, Hour 5 | -15.7 ± 15.72 |
| Change at Day 1, Hour 6 | -12.8 ± 9.32 |
VAS-L is a subject-rated scale used to assess the perceived loudness of tinnitus. Participants answered the question "How loud is your tinnitus now?" on a horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. A Mixed Model Repeated Measures (MMRM) with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.
| score on a scale | Brexanolone |
|---|---|
| Change at Day 1, Hour 0.5 | -3.10 ± 2.486 |
| Change at Day 1, Hour 1 | -8.10 ± 4.441 |
| Change at Day 1, Hour 2 | -7.20 ± 4.472 |
| Change at Day 1, Hour 3 | -11.20 ± 4.474 |
| Change at Day 1, Hour 4 | -15.40 ± 5.043 |
| Change at Day 1, Hour 5 | -15.70 ± 4.826 |
| Change at Day 1, Hour 6 | -12.80 ± 3.013 |
VAS-A is a subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on a horizontal scale anchored on the left by "not annoying" (score of 0) and on the right by "extremely annoying" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.
| score on a scale | Brexanolone |
|---|---|
| Change at Day 1, Hour 0.5 | -7.6 ± 13.45 |
| Change at Day 1, Hour 1 | -9.8 ± 18.74 |
| Change at Day 1, Hour 2 | -16.6 ± 28.68 |
| Change at Day 1, Hour 3 | -16.9 ± 20.00 |
| Change at Day 1, Hour 4 | -21.3 ± 28.07 |
| Change at Day 1, Hour 5 | -22.0 ± 27.71 |
| Change at Day 1, Hour 6 | -22.3 ± 20.92 |
VAS-A is a subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on a horizontal scale anchored on the left by "not annoying" (score of 0) and on the right by "extremely annoying" (score of 100). Higher scores represent greater severity. Negative change from baseline represents better outcome of the treatment. A MMRM with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. For the treatment period (Day 1), baseline was defined as the most recent value immediately prior to the start of brexanolone infusion, or predose.
| score on a scale | Brexanolone |
|---|---|
| Change at Day 1, Hour 0.5 | -7.60 ± 4.088 |
| Change at Day 1, Hour 1 | -9.80 ± 5.193 |
| Change at Day 1, Hour 2 | -16.60 ± 8.108 |
| Change at Day 1, Hour 3 | -16.90 ± 5.790 |
| Change at Day 1, Hour 4 | -21.30 ± 7.980 |
| Change at Day 1, Hour 5 | -22.00 ± 7.882 |
| Change at Day 1, Hour 6 | -22.30 ± 5.167 |
VAS-L is subject-rated scale used to assess perceived loudness of tinnitus. Participants answered question "How loud is your tinnitus now?" on horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100) via daily diary over multiple days. Higher scores= greater severity. Negative change from baseline= better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.
| score on a scale | Brexanolone |
|---|---|
| Change at Day 2 | -17.56 ± 19.125 |
| Change at Day 3 | -17.51 ± 22.231 |
| Change at Day 4 | -15.61 ± 20.084 |
| Change at Day 5 | -16.76 ± 22.388 |
| Change at Day 6 | -16.96 ± 22.235 |
| Change at Day 7 | -11.31 ± 19.509 |
VAS-L is subject-rated scale used to assess perceived loudness of tinnitus. Participants answered question "How loud is your tinnitus now?" on horizontal scale anchored on left by "not audible" (score of 0) and on right by "extremely loud" (score of 100) via daily diary over multiple days. Higher scores= greater severity. Negative change from baseline= better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. A MMRM with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.
| score on a scale | Brexanolone |
|---|---|
| Change at Day 2 | -17.56 ± 6.769 |
| Change at Day 3 | -17.51 ± 8.035 |
| Change at Day 4 | -15.61 ± 6.805 |
| Change at Day 5 | -16.76 ± 8.064 |
| Change at Day 6 | -16.96 ± 7.721 |
| Change at Day 7 | -11.31 ± 7.330 |
VAS-A is subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on horizontal scale anchored on left by "not annoying" (score of 0) and on right by "extremely annoying" (score of 100) via daily diary over multiple days. Higher scores=greater severity. Negative change from baseline=better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.
| score on a scale | Brexanolone |
|---|---|
| Change at Day 2 | -19.41 ± 19.492 |
| Change at Day 3 | -16.01 ± 21.161 |
| Change at Day 4 | -13.41 ± 23.037 |
| Change at Day 5 | -15.16 ± 26.075 |
| Change at Day 6 | -11.51 ± 27.493 |
| Change at Day 7 | -7.61 ± 23.659 |
VAS-A is subject-rated scale used to assess the tinnitus. Participants answered the question "How much is your tinnitus annoying you now?" on horizontal scale anchored on left by "not annoying" (score of 0) and on right by "extremely annoying" (score of 100) via daily diary over multiple days. Higher scores=greater severity. Negative change from baseline=better outcome of treatment. For remote assessments (Day 2 through 7), ratings were obtained twice daily (morning and evening). Daily arithmetic mean was calculated by averaging morning and evening scores. If a participant was missing either a morning or evening score, then single available score was used as the mean for that day. A MMRM with fixed effects for baseline VAS component value and change from baseline scores as the dependent variable is used. Baseline is defined as the average value of Day -7 to Day -1 measurements. This was calculated by summing daily arithmetic means and dividing by total number of non-missing days.
| score on a scale | Brexanolone |
|---|---|
| Change at Day 2 | -19.41 ± 7.266 |
| Change at Day 3 | -16.01 ± 8.111 |
| Change at Day 4 | -13.41 ± 8.288 |
| Change at Day 5 | -15.16 ± 8.716 |
| Change at Day 6 | -11.51 ± 9.523 |
| Change at Day 7 | -7.61 ± 8.078 |
Collected over Up to Day 15. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexanolone | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| Event | Brexanolone |
|---|---|
| TinnitusEar and labyrinth disorders | 1/10 |
Safety set included all participants who received any amount of brexanolone.
| Age, Continuous(years) | Brexanolone |
|---|---|
| Mean | 48.8 ± 9.96 |
| Sex: Female, Male(Participants) | Brexanolone |
|---|---|
| Female | 7 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | Brexanolone |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Brexanolone |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 4 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.
Ran from May 2023 to primary completion in Nov 2023, 6 months.
Results were first posted in Dec 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexanolone
Supernus Pharmaceuticals, Inc. →